Part of the firm’s Incromega range, ‘3mulsion’ will feature at Vitafoods Europe in Geneva in May, with the company saying market testing has indicated a separation issue.
“Incromeg 3mulsion has been tested against existing branded omega-3 emulsions,” said David Jopling, Croda Health Care business development manager in functional food.
“These branded emulsions have been found to have separated – fish oil splitting out from the emulsion – inside their packaging, whereas Incromega 3mulsion is highly stable and does not separate.”
He said this had been achieved, “by using the right proportion of emulsifying agents”.
The offering comes in a 250mg omega-3 blend of 250mg DHA (docosahexaenoic acid) and 25mg of EPA (eicosapentaenoic acid) aimed at children that may not wish to take supplements, or whose parents may not wish them too.
The company said the formulation had been arrived with European Union-approved omega-3 claims in mind including the claim: “DHA intake can contribute to normal brain development of the foetus, infant and young children.”
While the current launch was aimed at infants and children, R&D work was ongoing for other products.
“The high DHA to EPA ratio product is being targeted mainly at brands wishing to focus on improving the omega 3 intake of young children,” Jopling said.
“New variants of the formulation are underway, utilising different ratios of DHA and EPA to meet customer’s varying target market requirements.”
Laura Kelly, marketing manager at Croda, added: “The market for omega-3 softgel capsules has experienced significant growth in the last few years however, we recognise that this delivery form does not suit everyone. The flavoured 3mulsion can be included into single-serve sachets and syrups, perfect to be taken as a sweet treat after dinner or to be added to a children’s lunch box.”